Breast cancer chemotherapy
This article needs attention from an expert in Medicine.(February 2009)
|Breast cancer chemotherapy|
There are three major types of chemotherapy.
- Neoadjuvant chemotherapy
- Neoadjuvant chemo is given before surgery to slow the growth of a fast growing cancer or to shrink the size of a larger breast cancer.
- So, neoadjuvant chemo is frequently used to treat locally advanced cancers, cancers that at the time of diagnosis are too big to be removed by surgery, which can then be removed with less extensive surgery.
- Adjuvant chemotherapy
- Palliative chemotherapy
- Palliative chemo is used to control (but not cure) the cancer in settings in which the cancer has spread beyond the breast and localized lymph nodes. See metastatic breast cancer.
- Combined therapies
- Combining, for example, non-drug treatments with localized chemotherapy to limit toxicity and achieve better results.
Multiple chemotherapeutic agents may be used in combination to treat patients with breast cancer. Determining the appropriate regimen to use depends on many factors; such as, the character of the tumor, lymph node status, and the age and health of the patient.
The following is a list of some of the commonly used adjuvant chemotherapy for breast cancer:
- CMF: cyclophosphamide, methotrexate, and 5-fluorouracil.
- FAC (or CAF): 5-fluorouracil, doxorubicin, cyclophosphamide.
- AC (or CA): Adriamycin (doxorubicin) and cyclophosphamide.
- AC-Taxol: AC followed by paclitaxel (Taxol).
- TAC: Taxotere (docetaxel), Adriamycin (doxorubicin), and cyclophosphamide.
- FEC: 5-fluorouracil, epirubicin and cyclophosphamide.
- AT: Adriamycin (doxorubicin) and Taxotere (docetaxel).
Since chemotherapy affects the production of white blood cells, a granulocyte colony-stimulating factor (G-CSF) is sometimes administered along with chemotherapy. This has been shown to reduce, though not completely prevent, the rate of infection and low white cell count. Most adjuvant breast cancer chemotherapy regimens do not routinely require growth factor support except for those associated with a high incidence of bone marrow suppression and infection. These may include chemotherapy given in the dose dense fashion i.e. 2-weekly instead of 3-weekly or TAC chemotherapy (see above).
By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines.
CEP17 is detected by a common and straightforward test (fluorescent in situ hybridisation or FISH), which is carried out routinely in breast cancer patients; it is used to test for the HER2 gene to see whether the women might benefit from the drug Herceptin. Professor Bartlett said that assessment for CEP17 could be easily carried out in the same FISH analysis as for HER2. 
For breast cancer, chemotherapy drugs are given into a vein (intravenously) or by mouth as tablets or capsules (orally).
- "Chemotherapy". Breast Cancer Care. 2016-10-26. Retrieved 2018-04-20.
- "Chemotherapy for Breast Cancer". www.cancer.org. Retrieved 2018-04-20.
- "Choosing a Chemotherapy Combination to Treat Breast Cancer | Breastcancer.org". Breastcancer.org. Retrieved 2018-04-20.
- "Breakthrough - CMF (cyclophosphamide, methotrexate and 5-fluorouracil)". 2009-01-06. Retrieved 2018-04-20.
- "CAF". National Cancer Institute. Retrieved 2018-04-20.
- "AC". National Cancer Institute. Retrieved 2018-04-20.
- "AC-T". National Cancer Institute. Retrieved 2018-04-20.
- "TAC". National Cancer Institute. Retrieved 2018-04-20.
- "FEC". National Cancer Institute. Retrieved 2018-04-20.
- Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (October 2013). "The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials". Annals of Oncology. 24 (10): 2475–84. doi:10.1093/annonc/mdt226. PMC 3841419. PMID 23788754.
- Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI (May 2015). "Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also". Journal of Clinical Oncology. 33 (15): 1680–7. doi:10.1200/JCO.2013.54.7869. PMID 25897160.
- PDQ Adult Treatment Editorial Board (2002). PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US). PMID 26389406.